The role of immune and inflammatory mechanisms in ALS

Current Molecular Medicine

Volumn 11, Issue 3, 2011, Pages 246-254

  McCombe, P A ^a   Henderson, R D ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Amyotrophic lateral sclerosis; Biomarkers; Immunity; Inflammation; Lymphocytes; Protective immunity; T cells

Indexed keywords

AZATHIOPRINE; BENZODIAZEPINE RECEPTOR; C REACTIVE PROTEIN; CASPASE; CASPASE 3; CASPASE INHIBITOR; CD40 LIGAND; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5A; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOPHOSPHAMIDE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MINOCYCLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MUTANT PROTEIN; PREDNISONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SOMATOMEDIN C; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4; UNINDEXED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CEREBROSPINAL FLUID; CLINICAL FEATURE; CYTOKINE RELEASE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE TRANSMISSION; DRUG TREATMENT FAILURE; ENVIRONMENTAL FACTOR; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFLAMMATION; MICROGLIA; NERVOUS SYSTEM; NONHUMAN; OCCUPATIONAL EXPOSURE; PATHOGENESIS; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TISSUE REPAIR; TRANSGENIC MOUSE;

ANIMALIA;

EID: 79953297965     PISSN: 15665240     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652411795243450     Document Type: Article

References (142)

1. Holmoy T. T cells in amyotrophic lateral sclerosis. Eur J Neurol 2008; 15: 360-366.
2. Calvo A, Moglia C, Balma M, Chio A. Involvement of immune response in the pathogenesis of amyotrophic lateral sclerosis: a therapeutic opportunity? CNS Neurol Disord Drug Targets 2010; 9: 325-330.
3. Barbeito AG, Mesci P, Boillee S. Motor neuron-immune interactions: the vicious circle of ALS. J Neural Transm 2010; 117: 981-1000.
4. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993; 14: 426-430.
5. Papadimitriou D, Le V, V, Jacquier A, Ikiz B, Przedborski S, Re DB. Inflammation in ALS and SMA: Sorting out the good from the evil. Neurobiol Dis 2010; 37: 493-502.
6. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
7. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464: 104-107.
8. Graeber MB. Changing face of microglia. Science 2010; 330: 783-788.
9. Schwartz M, Cohen I, Lazarov-Spiegler O, Moalem G, Yoles E. The remedy may lie in ourselves: prospects for immune cell therapy in central nervous system protection and repair. J Mol Med 1999; 77: 713-717.
10. Graber JJ, Dhib-Jalbut S. Protective autoimmunity in the nervous system. Pharmacol Ther 2009; 121: 147-159.
11. Abhinav K, Stanton B, Johnston C, et al. Amyotrophic lateral sclerosis in South-East England: a population-based study. The South-East England register for amyotrophic lateral sclerosis (SEALS Registry). Neuroepidemiology 2007; 29: 44-48.
12. Vazquez MC, Ketzoian C, Legnani C, et al. Incidence and prevalence of amyotrophic lateral sclerosis in Uruguay: a population-based study. Neuroepidemiology 2008; 30: 105-111.
13. Chio A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology 2009; 72: 725-731.
14. Beghi E, Millul A, Micheli A, Vitelli E, Logroscino G. Incidence of ALS in Lombardy, Italy. Neurology 2007; 68: 141-145.
15. McGuire V, Longstreth WT, Jr., Koepsell TD, van BG. Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. Neurology 1996; 47: 571-573.
16. McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med 2010; 7: 557-570.
17. World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House Therapeutic Trials in ALS Workshop Contributors. J Neurol Sci 1995; 129 Suppl: 1-10.
18. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol 2000; 57: 1171-1176.
19. Geser F, Martinez-Lage M, Kwong LK, Lee VM, Trojanowski JQ. Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. J Neurol 2009; 256: 1205-1214.
20. Heads T, Pollock M, Robertson A, Sutherland WHF, Allpress S. Sensory nerve pathology in amyotrophic lateral sclerosis. Acta Neuropathol Berl 1991; 82: 316-320.
21. Chida K, Sakamaki S, Takasu T. Alteration in autonomic function and cardiovascular regulation in amyotrophic lateral sclerosis. J Neurol 1989; 236: 127-130.
22. Talman P, Forbes A, Mathers S. Clinical phenotypes and natural progression for motor neuron disease: analysis from an Australian database. Amyotroph Lateral Scler 2009; 10: 79-84.
23. Ganesalingam J, Stahl D, Wijesekera L, et al. Latent cluster analysis of ALS phenotypes identifies prognostically differing groups. PLoS ONE 2009; 4: e7107.
24. Dunckley T, Huentelman MJ, Craig DW, et al. Wholegenome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med 2007; 357: 775-788.
25. Beghi E, Chio A, Couratier P, et al. The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler 2011; 12: 1-10.
26. del Aguila MA, Longstreth WT, Jr., McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003; 60: 813-819.
27. McCombe PA, Greer JM, Mackay IR. Sexual dimorphism in autoimmune disease. Curr Mol Med 2009; 9: 1058-1079.
28. Carratu P, Spicuzza L, Cassano A, et al. Early treatment with noninvasive positive pressure ventilation prolongs survival in Amyotrophic Lateral Sclerosis patients with nocturnal respiratory insufficiency. Orphanet J Rare Dis 2009; 4: 10.
29. Baumann F, Henderson RD, Morrison SC, et al. Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009; 1-9.
30. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009; 8: 94-109.
31. Daube JR. Motor unit number estimates--from A to Z. J Neurol Sci 2006; 242: 23-35.
32. Ridall PG, Pettitt AN, Henderson RD, McCombe PA. Motor Unit Number Estimation-A Bayesian Approach. Biometrics 2006; 62: 1235-1250.
33. Ridall PG, Pettitt AN, Friel N, McCombe PA, Henderson RD. Motor unit number estimation using reversible jump Markov chain Monte Carlo. Journal Royal Statistical Society Series C - Applied Statistics 2007; 56: 235-269.
34. Henderson RD, Ridall PG, Hutchinson NM, Pettitt AN, McCombe PA. Bayesian statistical MUNE method. Muscle Nerve 2007; 36: 206-213.
35. Boylan K, Yang C, Crook J, et al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem 2009; 111: 1182-1191.
36. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009; 65 Suppl 1: S3-S9.
37. Liscic RM, Grinberg LT, Zidar J, Gitcho MA, Cairns NJ. ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol 2008; 15: 772-780.
38. Buratti E, Baralle FE. The molecular links between TDP-43 dysfunction and neurodegeneration. Adv Genet 2009; 66: 1-34.
39. Shi P, Gal J, Kwinter DM, Liu X, Zhu H. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochim Biophys Acta 2010; 1802: 45-51.
40. Kwak S, Hideyama T, Yamashita T, Aizawa H. AMPA receptor-mediated neuronal death in sporadic ALS. Neuropathology 2010; 30: 182-188.
41. Shibata N, Kakita A, Takahashi H, et al. Increased expression and activation of cytosolic phospholipase A(2) in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. Acta Neuropathol Berl 2010. [Epub ahead of print]
42. Shibata N, Kakita A, Takahashi H, et al. Persistent cleavage and nuclear translocation of apoptosis-inducing factor in motor neurons in the spinal cord of sporadic amyotrophic lateral sclerosis patients. Acta Neuropathol Berl 2009. [Epub ahead of print]
43. Aebischer J, Cassina P, Otsmane B, et al. IFNgamma triggers a LIGHT-dependent selective death of motoneurons contributing to the non-cell-autonomous effects of mutant SOD1. Cell Death Differ 2010. [Epub ahead of print]
44. Boillee S, Vande VC, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006; 52: 39-59.
45. Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009; 187: 761-772.
46. Orrell RW, Habgood JJ, Malaspina A, et al. Clinical characteristics of SOD1 gene mutations in UK families with ALS. J Neurol Sci 1999; 169: 56-60.
47. Blair IP, Williams KL, Warraich ST, et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry 2010; 81(6): 639-645.
48. Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008; 40: 572-574.
49. Fang F, Kamel F, Lichtenstein P, et al. Familial aggregation of amyotrophic lateral sclerosis. Ann Neurol 2009; 66: 94-99.
50. Lai SL, Abramzon Y, Schymick JC, et al. FUS mutations in sporadic amyotrophic lateral sclerosis. Neurobiol Aging 2010. [Epub ahead of print]
51. Corcia P, Camu W, Praline J, Gordon PH, Vourch P, Andres C. The importance of the SMN genes in the genetics of sporadic ALS. Amyotroph Lateral Scler 2009; 10: 436-440.
52. Sha Q, Zhang Z, Schymick JC, Traynor BJ, Zhang S. Genome-wide association reveals three SNPs associated with sporadic amyotrophic lateral sclerosis through a twolocus analysis. BMC Med Genet 2009; 10: 86.
53. Blauw HM, Al-Chalabi A, Andersen PM, et al. A large genome scan for rare CNVs in amyotrophic lateral sclerosis. Hum Mol Genet 2010; 19: 4091-4099.
54. Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology 2009; 73: 1693-1698.
55. Chio A, Calvo A, Dossena M, Ghiglione P, Mutani R, Mora G. ALS in Italian professional soccer players: the risk is still present and could be soccer-specific. Amyotroph Lateral Scler 2009; 10: 205-209.
56. Beghi E, Logroscino G, Chio A, et al. Amyotrophic lateral sclerosis, physical exercise, trauma and sports: results of a population-based pilot case-control study. Amyotroph Lateral Scler 2010; 11: 289-292.
57. Sutedja NA, Veldink JH, Fischer K, et al. Lifetime occupation, education, smoking, and risk of ALS. Neurology 2007; 69: 1508-1514.
58. Fang F, Quinlan P, Ye W, et al. Workplace exposures and the risk of amyotrophic lateral sclerosis. Environ Health Perspect 2009; 117: 1387-1392.
59. Furby J, Hayton T, Anderson V, et al. Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler 2008; 14: 1068-1075.
60. Sutedja NA, Veldink JH, Fischer K, et al. Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler 2009;10: 302-309.
61. Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol 1993; 50: 30-36.
62. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002; 26: 459-470.
63. McGeer PL, McGeer EG, Kawamata T, Yamada T, Akiyama H. Reactions of the immune system in chronic degenerative neurological diseases. Can J Neurol Sci 1991; 18: 376-379.
64. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996; 19: 312-318.
65. Shibata N, Kakita A, Takahashi H, et al. Activation of signal transducer and activator of transcription-3 in the spinal cord of sporadic amyotrophic lateral sclerosis patients. Neurodegener Dis 2009; 6: 118-126.
66. Zhang R, Hadlock KG, Do H, et al. Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 2011; 230: 114-123.
67. Winkeler A, Boisgard R, Martin A, Tavitian B. Radioisotopic imaging of neuroinflammation. J Nucl Med 2010; 51: 1-4.
68. Le Fur G, Perrier ML, Vaucher N, et al. Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci 1983; 32: 1839-1847.
69. Cagnin A, Kassiou M, Meikle SR, Banati RB. Positron emission tomography imaging of neuroinflammation. Neurotherapeutics 2007; 4: 443-452.
70. Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 2004; 15: 601-609.
71. Fischer LR, Culver DG, Tennant P, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 2004; 185: 232-240.
72. Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992; 140: 691-707.
73. Graves MC, Fiala M, Dinglasan LA, et al. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 213-219.
74. Lawson JM, Tremble J, Dayan C, et al. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol 2008; 154: 353-359.
75. Holmoy T, Roos PM, Kvale EO. ALS: cytokine profile in cerebrospinal fluid T-cell clones. Amyotroph Lateral Scler 2006; 7: 183-186.
76. Engelhardt JI, Appel SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 1990; 47: 1210-1216.
77. Donnenfeld H, Kascsak RJ, Bartfeld H. Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J Neuroimmunol 1984; 6: 51-57.
78. Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007; 61: 427-434.
79. Yang WW, Sidman RL, Taksir TV, et al. Relationship between neuropathology and disease progression in the SOD1(G93A) ALS mouse. Exp Neurol 2010.
80. Sanagi T, Yuasa S, Nakamura Y, et al. Appearance of phagocytic microglia adjacent to motoneurons in spinal cord tissue from a presymptomatic transgenic rat model of amyotrophic lateral sclerosis. J Neurosci Res 2010; 88: 2736-2746.
81. Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 2001; 57: 1282-1289.
82. Pasinelli P, Houseweart MK, Brown RH, Jr., Cleveland DW. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000; 97: 13901-13906.
83. Engelhardt JI, Siklos L, Komuves L, Smith RG, Appel SH. Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons. Synapse 1995; 20: 185-199.
84. Kimura F, Smith RG, Delbono O, et al. Amyotrophic lateral sclerosis patient antibodies label Ca2+ channel alpha 1 subunit. Ann Neurol 1994; 35: 164-171.
85. Saleh IA, Zesiewicz T, Xie Y, et al. Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression. J Neuroimmunol 2009; 215: 96-101.
86. Zhang R, Gascon R, Miller RG, et al. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 2005; 159: 215-224.
87. Mantovani S, Garbelli S, Pasini A, et al. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J Neuroimmunol 2009; 210: 73-79.
88. Fiala M, Chattopadhay M, La CA, et al. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflammation 2010; 7: 76.
89. Shi N, Kawano Y, Tateishi T, et al. Increased IL-13- producing T cells in ALS: positive correlations with disease severity and progression rate. J Neuroimmunol 2007; 182: 232-235.
90. Lincecum JM, Vieira FG, Wang MZ, et al. From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet 2010; 42: 392-399.
91. Kuhle J, Lindberg RL, Regeniter A, et al. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol 2009; 16: 771-774.
92. Zhang R, Gascon R, Miller RG, et al. MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 2006; 179: 87-93.
93. Moreau C, Devos D, Brunaud-Danel V, et al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology 2005; 65: 1958-1960.
94. Zhang R, Miller RG, Gascon R, et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 2009; 206: 121-124.
95. Goldknopf IL, Sheta EA, Bryson J, et al. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem Biophys Res Commun 2006; 342: 1034-1039.
96. Keizman D, Rogowski O, Berliner S, et al. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2009; 119: 383-389.
97. Wills AM, Cronin S, Slowik A, et al. A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS. Neurology 2009; 73: 16-24.
98. Appel SH, Beers DR, Henkel JS. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol 2010; 31: 7-17.
99. Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 2009; 132: 288-295.
100. Schwartz M, Moalem G. Beneficial immune activity after CNS injury: prospects for vaccination. J Neuroimmunol 2001; 113: 185-192.
101. Cohen IR, Schwartz M. Autoimmune maintenance and neuroprotection of the central nervous system. J Neuroimmunol 1999; 100: 111-114.
102. Stoll G, Jander S, Schroeter M. Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol 2002; 513: 87-113.
103. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. Neurol Sci 2006; 27 Suppl 1: S1-S7.
104. Hohlfeld R. Does inflammation stimulate remyelination? J Neurol 2007; 254 Suppl 1: I47-I54.
105. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol 2000; 107: 161-166.
106. Schwartz M, Kipnis J. Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. Trends Mol Med 2001; 7: 252-258.
107. Appel SH, Engelhardt JI, Garcia J, Stefani E. Immunoglobulins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction. Proc Natl Acad Sci USA 1991; 88: 647-651.
108. Pullen AH, Demestre M, Howard RS, Orrell RW. Passive transfer of purified IgG from patients with amyotrophic lateral sclerosis to mice results in degeneration of motor neurons accompanied by Ca2+ enhancement. Acta Neuropathol Berl 2004; 107: 35-46.
109. Demestre M, Pullen A, Orrell RW, Orth M. ALS-IgG-induced selective motor neurone apoptosis in rat mixed primary spinal cord cultures. J Neurochem 2005; 94: 268-275.
110. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989; 169: 59-72.
111. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164: 6166-6173.
112. Heiman-Patterson TD, Deitch JS, Blankenhorn EP, et al. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J Neurol Sci 2005; 236: 1-7.
113. Heiman-Patterson TD, Sher RB, Blankenhorn EA, et al. Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: A window of opportunity in the search for genetic modifiers. Amyotroph Lateral Scler 2011.
114. Nguyen MD, D'Aigle T, Gowing G, Julien JP, Rivest S. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J Neurosci 2004; 24: 1340-1349.
115. Lehnardt S, Massillon L, Follett P, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci USA 2003; 100: 8514-8519.
116. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 268-278.
117. Keller AF, Gravel M, Kriz J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol 2010.
118. Yang EJ, Jiang JH, Lee SM, et al. Bee venom attenuates neuroinflammatory events and extends survival in amyotrophic lateral sclerosis models. J Neuroinflammation 2010; 7: 69.
119. Cassel SL, Sutterwala FS. Sterile inflammatory responses mediated by the NLRP3 inflammasome. Eur J Immunol 2010; 40: 607-611.
120. Conforti-Andreoni C, Ricciardi-Castagnoli P, Mortellaro A. The inflammasomes in health and disease: from genetics to molecular mechanisms of autoinflammation and beyond. Cell Mol Immunol 2011.
121. Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci USA 2010; 107: 13046-13050.
122. Woodruff TM, Costantini KJ, Crane JW, et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol 2008; 181: 8727-8734.
123. Naor S, Keren Z, Bronshtein T, Goren E, Machluf M, Melamed D. Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes. J Neurol 2009; 256: 1228-1235.
124. Gowing G, Philips T, Van WB, et al. Ablation of proliferating microglia does not affect motor neuron degeneration in amyotrophic lateral sclerosis caused by mutant superoxide dismutase. J Neurosci 2008; 28: 10234-10244.
125. Schwartz M, Moalem G, Leibowitz-Amit R, Cohen IR. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci 1999; 22: 295-299.
126. Banerjee R, Mosley RL, Reynolds AD, et al. Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS ONE 2008; 3: e2740.
127. Takeuchi S, Fujiwara N, Ido A, et al. Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J Neuropathol Exp Neurol 2010; 69: 1044-1056.
128. Chiu IM, Chen A, Zheng Y, et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci USA 2008; 105: 17913-17918.
129. Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A 2008; 105: 15558-15563.
130. Mosley RL, Gendelman HE. Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders. Exp Neurol 2010; 222: 1-5.
131. Kosloski LM, Ha DM, Hutter JA, et al. Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. J Neurochem 2010; 114: 1261-1276.
132. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6: 1045-1053.
133. Appel SH, Engelhardt JI, Henkel JS, et al. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 2008; 71: 1326-1334.
134. Meucci N, Nobile-Orazio E, Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol 1996; 243: 117-120.
135. Smith SA, Miller RG, Murphy JR, Ringel SP. Treatment of ALS with high dose pulse cyclophosphamide. J Neurol Sci 1994; 124 Suppl: 84-87.
136. Werdelin L, Boysen G, Jensen TS, Mogensen P. Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 1990; 82: 132-134.
137. Chio A, Mora G, Bella VL, et al. Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicenter study. Muscle Nerve 2011; 43: 189-195.
138. Al-Chalabi A, Fang F, Hanby MF, Leigh PN, Shaw CE, Ye W et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry 2010; 81: 1324-1326.
139. Wang JH, Pappas D, De Jager PL, et al. Modeling the Cumulative Genetic Risk for Multiple Sclerosis from Genome Wide Association Data. Genome Med 2011; 3:3.
140. Galimberti D, Scarpini E. Inflammation and oxidative damage in Alzheimer's disease: friend or foe? Front Biosci (Schol Ed) 2011; 3: 252-266.
141. Barnum CJ, Tansey MG. Modeling neuroinflammatory pathogenesis of Parkinson's disease. Prog Brain Res 2010; 184: 113-132.
142. McCombe PA, Read SJ. Immune and inflammatory responses to stroke: good or bad? Int J Stroke 2008; 3: 254-265.